Holen Sie sich die Stockscreener-App
57.73
1.25%
-0.73
Handel nachbörslich:
57.75
0.02
+0.03%
Schlusskurs vom Vortag:
$58.46
Offen:
$58.41
24-Stunden-Volumen:
1.46M
Relative Volume:
0.80
Marktkapitalisierung:
$11.26B
Einnahmen:
$4.08B
Nettoeinkommen (Verlust:
$32.48M
KGV:
412.36
EPS:
0.14
Netto-Cashflow:
$16.80M
1W Leistung:
-1.92%
1M Leistung:
-14.93%
6M Leistung:
-12.76%
1J Leistung:
+8.47%
1-Tages-Spanne:
$57.05
$58.78
1-Wochen-Bereich:
$53.79
$59.95
52-Wochen-Spanne:
$50.35
$83.95
Incyte Corp Stock (INCY) Company Profile
Firmenname
Incyte Corp
Sektor
Branche
Telefon
(302) 498-6700
Adresse
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Vergleichen Sie INCY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
57.73 | 11.26B | 4.08B | 32.48M | 16.80M | 0.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
485.89 | 126.49B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
549.28 | 59.71B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
587.59 | 36.26B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
230.50 | 29.48B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
228.14 | 25.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-18 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-03-18 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-12-17 | Eingeleitet | UBS | Neutral |
| 2024-10-29 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-10-01 | Eingeleitet | Wolfe Research | Outperform |
| 2024-09-18 | Herabstufung | Truist | Buy → Hold |
| 2024-07-02 | Herabstufung | BMO Capital Markets | Market Perform → Underperform |
| 2024-05-23 | Eingeleitet | Deutsche Bank | Hold |
| 2024-04-23 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2024-02-23 | Eingeleitet | Jefferies | Buy |
| 2024-02-14 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-13 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2023-12-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-11-21 | Herabstufung | Goldman | Buy → Neutral |
| 2023-07-25 | Eingeleitet | Citigroup | Buy |
| 2023-05-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-04-10 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-03-24 | Hochstufung | SVB Securities | Underperform → Market Perform |
| 2023-01-31 | Eingeleitet | Piper Sandler | Overweight |
| 2022-08-03 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-08-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-07-28 | Eingeleitet | Wells Fargo | Equal Weight |
| 2022-02-09 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2022-01-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2021-07-20 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2021-02-10 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2021-01-07 | Eingeleitet | Truist | Buy |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-06-16 | Eingeleitet | The Benchmark Company | Hold |
| 2020-05-06 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-04-29 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-24 | Fortgesetzt | William Blair | Outperform |
| 2020-03-13 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2020-02-04 | Fortgesetzt | BofA/Merrill | Neutral |
| 2020-01-03 | Bestätigt | BMO Capital Markets | Market Perform |
| 2020-01-03 | Herabstufung | Mizuho | Buy → Neutral |
| 2020-01-02 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-10-03 | Eingeleitet | Mizuho | Buy |
| 2019-09-12 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2019-09-05 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-09-05 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2019-09-05 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2019-05-21 | Eingeleitet | Credit Suisse | Neutral |
| 2019-05-03 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2019-04-11 | Eingeleitet | Stifel | Hold |
| 2019-04-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-01-24 | Hochstufung | William Blair | Mkt Perform → Outperform |
Alle ansehen
Incyte Corp Aktie (INCY) Neueste Nachrichten
Incyte to Announce Q1 2025 Financial Results on April 29 - MyChesCo
Incyte Earnings Preview: What To Expect - Barchart.com
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Incyte Grants Restricted Stock Units to New Employees - MyChesCo
Incyte (INCY) Revenue Surges, But Stock Drops 20% - GuruFocus
Global Janus Kinase Inhibitors Market Surges at 8.4% CAGR - openPR.com
Incyte to Report First Quarter Financial Results | INCY Stock Ne - GuruFocus
Incyte to Report First Quarter Financial Results - Business Wire
Judges Skeptical of Incyte's Patent Block on Sun's Alopecia Drug - Bloomberg Law News
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 7, 2025 - BioSpace
Incyte Can't Get Pretrial Win In Novartis Royalty Fight - Law360
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MarketScreener
Immuno-Oncology Stocks Q4 Highlights: Incyte (NASDAQ:INCY) - Yahoo Finance
Incyte Co. (NASDAQ:INCY) Shares Sold by Mitsubishi UFJ Trust & Banking Corp - MarketBeat
Follicular Lymphoma Market to Reach New Heights in Growth - openPR.com
Follicular Lymphoma Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Roche, BeiGene, Kite Pharma, Incyte Corp, AstraZeneca, MEI Pharma, Novartis, Innovent Biologics, Regeneron - Barchart.com
1,764,725 Shares in Incyte Co. (NASDAQ:INCY) Acquired by Norges Bank - MarketBeat
Incyte Stock: Is INCY Outperforming the Health Care Sector? - Nasdaq
Incyte Stock: Is INCY Outperforming The Health Care Sector? - Barchart.com
3 Reasons INCY is Risky and 1 Stock to Buy Instead - Yahoo Finance
Women in healthcare and life sciences - The Business Journals
Incyte’s SWOT analysis: stock faces patent cliff challenge amid pipeline promise - Investing.com
Meiji Yasuda Asset Management Co Ltd. Purchases 32,830 Shares of Incyte Co. (NASDAQ:INCY) - MarketBeat
Incyte : U.S. FDA allows Lilly's COVID-19 drug to be taken without remdesivir - MarketScreener
Incyte Announces Positive Phase 3 Results for Hidradenitis Suppurativa Treatment - MSN
Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch
Incyte Had a Bad Week. Investors Are Used to It. - MSN
Leerink Partners Adjusts Price Target on Incyte to $92 From $100, Maintains Outperform Rating - MarketScreener
Incyte’s Hold Rating: Balancing Pipeline Challenges and Established Product Valuation - TipRanks
Compass Ion Advisors LLC Has $960,000 Position in Incyte Co. (NASDAQ:INCY) - MarketBeat
Monday.com, Incyte, Lucid, Bloom, EQT: Trending by Analysts - TipRanks
Why Incyte Stock Was Tanking This Week - MSN
Incyte (INCY) Stock Declines Due to Clinical Trial Results - GuruFocus.com
The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics - Yahoo Finance
Incyte EVP Barry Flannelly sells $1.34 million in stock - Investing.com India
Stock market unimpressed by results for Incyte acne drug as share price drops 11% - delawarebusinessnow.com
Incyte price target lowered to $72 from $74 at Truist - Yahoo Finance
William Blair Downgrades Incyte (BMV:INCY) - Nasdaq
Incyte EVP Barry Flannelly sells $1.34 million in stock By Investing.com - Investing.com South Africa
William Blair Downgrades Incyte (BIT:1INCY) - Nasdaq
Incyte: Still A 'Buy' Despite HS Treatment Data With Povorcitinib (NASDAQ:INCY) - Seeking Alpha
Marginal Zone Lymphoma Pipeline 2025: MOA and ROA Insights, - openPR
INCY Stock Down on Disappointing Skin Disease Study Data - Yahoo Finance
Incyte stock price target cut to $72 at Truist Securities - Investing.com India
This PepsiCo Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Benzinga
Incyte’s JAK1 blocker meets goals in Phase III trials - The Pharma Letter
Jefferies cuts Incyte stock price target to $75, keeps Buy rating - Investing.com
Mizuho maintains Incyte stock with $77 target, Neutral rating - Investing.com
Incyte divulges new MRGPRX2 antagonists - BioWorld MedTech
Citi maintains Buy on Incyte shares, reiterates $88 target - Investing.com
William Blair cuts Incyte stock rating post-trial results - Investing.com
Finanzdaten der Incyte Corp-Aktie (INCY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.21%
1.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):